查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1363076

美國臨床腫瘤學下一代定序市場規模、佔有率、趨勢分析報告：按工作流程、按技術、按應用、按最終用途、細分趨勢，2023-2030年

U.S. Clinical Oncology Next Generation Sequencing Market Size, Share & Trends Analysis Report By Workflow (NGS Pre-sequencing, NGS Sequencing, NGS Data Analysis), By Technology, By Application, By End-use, And Segment Forecasts, 2023 - 2030
出版日期: | 出版商: Grand View Research | 英文 90 Pages | 商品交期: 2-10個工作天內

價格

美國臨床腫瘤學下一代定序市場成長與趨勢

Grand View Research, Inc. 的最新報告顯示，到2030年，美國臨床腫瘤學下一代定序市場預計將達到 5.04 億美元。

預計2023年至2030年該市場將以15.1%的年複合成長率擴張。由於行業參與者之間的競爭加劇、領域的技術進步以及基因序列測定成本的降低，預計該市場在2023年至2030年的預測期內將顯著成長。

日益激烈的市場競爭以及基於腫瘤學領域次世代定序儀的創新解決方案的推出預計將在預測期內推動市場成長。例如，2023年2月，癌症篩檢和診斷測試公司Exact Sciences Corp.在美國推出了其治療選擇測試—OncoExTra。這是一種基於定序的下一代基因組測試，可以幫助癌症治療。幫助理解和表徵癌症腫瘤。此外，各公司共同努力，致力於次世代定序的進步，以獲得該行業的競爭優勢。例如，2020年 1月，市場上的兩家主要企業Illumina, Inc. 和 F. Hoffmann-La Roche Ltd. 簽署了一項為期 15 年的協議，以發現 NGS 改變癌症檢測、診斷、風險預測、治療和監測的潛力。

此外，還發表了有關 NGS 在腫瘤學和癌症治療中的應用的各種論文和研究。例如，2023年 6月，Lancet發表了一篇關於 NGS 測試在癌症患者中的真實結果和效用的論文。此外，2023年 6月，美國臨床腫瘤學會發表了一項關於 NGS 檢測對美國晚期癌症管理的臨床影響的研究。此類研究幫助研究人員和臨床醫生提高對 NGS 在癌症治療中的應用的認知和知識。

此外，由於定序成本的降低，預計預測期內臨床腫瘤學下一代定序市場的成長將會成長。透過增加平行定序和運作多個流動槽以提高定序容量，可以降低 NGS 的成本，而不會增加相關成本。預計這些因素將在預測期內增加美國的市場需求。

美國臨床腫瘤學下一代定序市場報告亮點

  • 根據工作流程細分，NGS 定序在2022年的收益佔有率最大，達到 55.6%。該領域的主導地位歸因於癌症測序計畫的增加和該領域的技術進步。
  • 從技術來看，標靶定序和重測序佔據市場主導地位，2022年收益佔有率為 72.9%。這是由於標靶化組合的使用增加及其在識別癌症腫瘤方面的效率。
  • 從應用來看，篩檢領域在美國臨床腫瘤NGS市場佔據主導地位，2022年收益佔有率為80.6%。
  • 根據最終用途，實驗室細分市場在2022年美國臨床腫瘤 NGS 市場中佔據最大佔有率，為 64.4%。該領域的主導地位是由於癌症治療的研發活動不斷增加。

目錄

第1章 調查方法與範圍

第2章 執行摘要

第3章 市場變數、趨勢和範圍

  • 市場體系展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場抑制因素分析
  • 產業分析工具
    • SWOT 分析；按因素（政治/法律、經濟/技術）
    • 波特五力分析
    • COVID-19感染疾病的影響分析

第4章 美國臨床腫瘤下一代定序市場分類：技術預估與趨勢分析

  • 美國臨床腫瘤NGS市場：技術變遷分析
  • 依技術
  • 全基因組序列測定
    • 全基因組定序市場，2018-2030
  • 全外顯子定序
    • 全外顯子定序市場，2018-2030
  • 標靶定序和重定序
    • 2018-2030年目標定序與重定序市場

第5章 美國臨床腫瘤次世代定序市場分類：工作流程估算與趨勢分析

  • 美國臨床腫瘤NGS市場：工作流程變化分析
  • 按工作流程
  • 5 NGS預測序
  • NGS定序
  • NGS資料分析

第6章 美國臨床腫瘤二代定序市場分類：應用預估及趨勢分析

  • 美國臨床腫瘤NGS市場：應用變化分析
  • 依最終用途
  • 篩選
    • 2018-2030年美國臨床腫瘤學 NGS 市場篩選
    • 散發性癌症
    • 遺傳性癌症
  • 伴隨診斷
    • 美國臨床腫瘤學 NGS 伴隨診斷市場，2018-2030年
  • 其他診斷
    • 美國臨床腫瘤學 NGS 其他診斷市場，2018-2030年

第7章 美國臨床腫瘤學下一代定序市場分類：最終用途估計和趨勢分析

  • 美國臨床腫瘤學 NGS 市場：最終用途變異分析
  • 依最終用途
  • 醫院
  • 診所
  • 實驗室

第8章 競爭形勢

  • 公司分類
  • 策略規劃
  • 公司簡介/名單
    • Illumina, Inc.
    • Thermo Fisher Scientific Inc.
    • F. Hoffmann-La Roche Ltd
    • Agilent Technologies, Inc.
    • Myriad Genetics, Inc.
    • Beijing Genomics Institute（BGI）
    • QIAGEN
    • Perkin Elmer, Inc.
    • PacBio
    • Oxford Nanopore Technologies
    • PerkinElmer Inc
    • Macrogen, Inc
Product Code: GVR-1-68038-168-9

U.S. Clinical Oncology Next Generation Sequencing Market Growth & Trends:

The U.S. clinical oncology next generation sequencing market is expected to reach USD 500.4 million by 2030, according to a new report by Grand View Research, Inc.. The market is expected to expand at a CAGR of 15.1% from 2023 to 2030. The market is expected to increase at a significant rate during the forecast period from 2023 to 2030 owing to the increasing competition among the industry players, technological advances in the field and decreasing costs for genetic sequencing.

The increasing market competition and the launch of innovative solutions based on next generation sequencing in the oncology field are expected to fuel market growth over the forecast period. For instance, in February 2023, Exact Sciences Corp., a cancer screening and diagnostic testing company, introduced the therapy selection test -OncoExTra in the U.S. It is a next-generation sequencing-based genomic test to help in cancer care. It helps in understanding and characterizing cancer tumors. Moreover, to gain a competitive edge in the industry, companies are collaborating and focusing on advancing in the next generation sequencing. For instance, in January 2020, the two key players operating in the market, Illumina, Inc and F. Hoffmann-La Roche Ltd, signed a 15-year agreement to discover NGS's potential to transform cancer detection, diagnosis, risk prediction, treatment, and monitoring.

Moreover, various articles and studies are being published on the use of NGS in oncology and cancer treatments. For instance, in June 2023, the Lancet published an article on real-world outcomes and the usefulness of NGS testing in cancer patients. Furthermore, in June 2023, the American Society Of Clinical Oncology published a study on the clinical impact of NGS tests for managing advanced cancer in the U.S. Such studies help researchers and clinicians increase awareness and knowledge about the use of NGS for cancer treatments.

Furthermore, the growth of the clinical oncology next-generation sequencing market during the forecast period is expected to witness growth due to reduced sequencing costs. The costs of NGS can be reduced by increasing parallel sequencing and running multiple flow cells to increase sequencing capacity without raising the costs associated with it. These factors are anticipated to boost the market demand over the forecast period in the U.S.

U.S. Clinical Oncology Next Generation Sequencing Market Report Highlights:

  • NGS sequencing accounted for the largest revenue share of 55.6% in 2022 based on the workflow segment. The dominance of the segments is due to the increasing number of cancer sequencing projects and technological advances in the field.
  • Based on the technology, targeted sequencing & resequencing dominated the market with a revenue share of 72.9% in 2022. This can be attributed to the rising use of targeted panels and their efficiency in identifying cancer tumors.
  • Based on the application, the screening segment dominated the U.S. clinical oncology NGS market with a revenue share of 80.6% in 2022, owing to the growing prevalence of cancer disorder across the country.
  • Based on the end-use, the laboratories segment accounted for the largest share of 64.4% in the U.S. clinical oncology NGS market in 2022. This dominance of the segment is due to the rising research and development activities for cancer treatment.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Information Procurement
  • 1.2. Information or Data Analysis
  • 1.3. Market Scope & Segment Definition
  • 1.4. Market Model
    • 1.4.1. Market Study, By Company Market Share

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Reduction in costs for genetic sequencing
      • 3.2.1.2. Advances in the field of personalized medicine
      • 3.2.1.3. Increase in prevalence of cancer
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Lack of computational efficiency for data management
  • 3.3. Industry Analysis Tools
    • 3.3.1. SWOT Analysis; By Factor (Political & Legal, Economic And Technological)
    • 3.3.2. Porter's Five Forces Analysis
    • 3.3.3. COVID-19 Impact Analysis

Chapter 4. U.S. Clinical Oncology Next Generation Sequencing Market Categorization: Technology Estimates & Trend Analysis

  • 4.1. U.S. clinical Oncology NGS Market: Technology Movement Analysis
  • 4.2. U.S. clinical Oncology NGS Market Estimates & Forecast, By Technology (USD Million)
  • 4.3. Whole Genome Sequencing
    • 4.3.1. Whole Genome Sequencing Market, 2018 - 2030 (USD Million)
  • 4.4. Whole Exome Sequencing
    • 4.4.1. Whole Exome Sequencing Market, 2018 - 2030 (USD Million)
  • 4.5. Targeted Sequencing & Resequencing
    • 4.5.1. Targeted Sequencing & Resequencing Market, 2018 - 2030 (USD Million)

Chapter 5. U.S. Clinical Oncology Next Generation Sequencing Market Categorization: Workflow Estimates & Trend Analysis

  • 5.1. U.S. clinical Oncology NGS Market: Workflow Movement Analysis
  • 5.2. U.S. clinical Oncology NGS Market Estimates & Forecast, By Workflow (USD Million)
  • 5.3. 5 NGS Pre-Sequencing
    • 5.3.1. NGS Pre-Sequencing Market, 2018 - 2030 (USD Million)
  • 5.4. NGS Sequencing
    • 5.4.1. NGS Sequencing Market, 2018 - 2030 (USD Million)
  • 5.5. NGS Data Analysis
    • 5.5.1. NGS Data Analysis Market, 2018 - 2030 (USD Million)

Chapter 6. U.S. Clinical Oncology Next Generation Sequencing Market Categorization: Application Estimates & Trend Analysis

  • 6.1. U.S. clinical Oncology NGS Market: Application Movement Analysis
  • 6.2. U.S. clinical Oncology NGS Market Estimates & Forecast, By End-User (USD Million)
  • 6.3. Screening
    • 6.3.1. Screening U.S. clinical Oncology NGS Market, 2018 - 2030 (USD Million)
    • 6.3.2. Sporadic Cancer
      • 6.3.2.1. Sporadic cancer screening U.S. clinical Oncology NGS Market, 2018 - 2030 (USD Million)
    • 6.3.3. Inherited cancer
      • 6.3.3.1. Inherited cancer screening U.S. clinical Oncology NGS Market, 2018 - 2030 (USD Million)
  • 6.4. Companion Diagnostics
    • 6.4.1. Companion diagnostics U.S. clinical Oncology NGS Market, 2018 - 2030 (USD Million)
  • 6.5. Other Diagnostics
    • 6.5.1. Other diagnostics U.S. clinical Oncology NGS Market, 2018 - 2030 (USD Million)

Chapter 7. U.S. Clinical Oncology Next Generation Sequencing Market Categorization: End Use Estimates & Trend Analysis

  • 7.1. U.S. clinical Oncology NGS Market: End Use Movement Analysis
  • 7.2. U.S. clinical Oncology NGS Market Estimates & Forecast, By End-User (USD Million)
  • 7.3. Hospitals
    • 7.3.1. Hospitals U.S. clinical Oncology NGS Market, 2018 - 2030 (USD Million)
  • 7.4. Clinics
    • 7.4.1. Clinics U.S. clinical Oncology NGS Market, 2018 - 2030 (USD Million)
  • 7.5. Laboratories
    • 7.5.1. Laboratories U.S. clinical Oncology NGS Market, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Company Categorization
  • 8.2. Strategy Mapping
  • 8.3. Company Profiles/Listing
    • 8.3.1. Illumina, Inc.
      • 8.3.1.1. Overview
      • 8.3.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.3.1.3. Product Benchmarking
      • 8.3.1.4. Strategic Initiatives
    • 8.3.2. Thermo Fisher Scientific Inc.
      • 8.3.2.1. Overview
      • 8.3.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.3.2.3. Product Benchmarking
      • 8.3.2.4. Strategic Initiatives
    • 8.3.3. F. Hoffmann-La Roche Ltd
      • 8.3.3.1. Overview
      • 8.3.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.3.3.3. Product Benchmarking
      • 8.3.3.4. Strategic Initiatives
    • 8.3.4. Agilent Technologies, Inc.
      • 8.3.4.1. Overview
      • 8.3.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.3.4.3. Product Benchmarking
      • 8.3.4.4. Strategic Initiatives
    • 8.3.5. Myriad Genetics, Inc.
      • 8.3.5.1. Overview
      • 8.3.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.3.5.3. Product Benchmarking
      • 8.3.5.4. Strategic Initiatives
    • 8.3.6. Beijing Genomics Institute (BGI)
      • 8.3.6.1. Overview
      • 8.3.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.3.6.3. Product Benchmarking
      • 8.3.6.4. Strategic Initiatives
    • 8.3.7. QIAGEN
      • 8.3.7.1. Overview
      • 8.3.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.3.7.3. Product Benchmarking
      • 8.3.7.4. Strategic Initiatives
    • 8.3.8. Perkin Elmer, Inc.
      • 8.3.8.1. Overview
      • 8.3.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.3.8.3. Product Benchmarking
      • 8.3.8.4. Strategic Initiatives
    • 8.3.9. PacBio
      • 8.3.9.1. Overview
      • 8.3.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.3.9.3. Product Benchmarking
      • 8.3.9.4. Strategic Initiatives
    • 8.3.10. Oxford Nanopore Technologies
      • 8.3.10.1. Overview
      • 8.3.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.3.10.3. Product Benchmarking
      • 8.3.10.4. Strategic Initiatives
    • 8.3.11. PerkinElmer Inc
      • 8.3.11.1. Overview
      • 8.3.11.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.3.11.3. Product Benchmarking
      • 8.3.11.4. Strategic Initiatives
    • 8.3.12. Macrogen, Inc
      • 8.3.12.1. Overview
      • 8.3.12.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.3.12.3. Product Benchmarking
      • 8.3.12.4. Strategic Initiatives

List of Tables

  • TABLE 1. Cancer Incidence and Mortality, 2018
  • TABLE 2. U.S. clinical Oncology NGS Market estimates & forecasts
  • TABLE 3. U.S. clinical Oncology NGS Market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • TABLE 4. U.S. clinical oncology NGS market estimates & forecasts, by workflow, 2018 - 2030 (USD Million)
  • TABLE 5. U.S. clinical oncology NGS market estimates & forecasts, by application, 2018 - 2030 (USD Million)
  • TABLE 6. U.S. clinical oncology NGS market estimates & forecasts, by end use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market snapshot
  • Fig. 2 Market research process
  • Fig. 3 Information procurement
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value chain based sizing & forecasting
  • Fig. 7 QFD modelling for market share assessment
  • Fig. 8 Market trends & outlook
  • Fig. 9 Market segmentation & scope
  • Fig. 10 Penetration & growth prospect mapping for application, 2022
  • Fig. 11 Penetration & growth prospect mapping for prominent industry players, 2022
  • Fig. 12 Market driver relevance analysis (Current & future impact)
  • Fig. 13 Cost per raw mega base (Mb) of DNA sequence (USD)
  • Fig. 14 Cost per genome
  • Fig. 15 Expected rise in expenditure for cancer treatment (USD Billion)
  • Fig. 16 Number of new cancer cases in the World, 2022
  • Fig. 17 Market restraint relevance analysis (Current & future impact)
  • Fig. 18 SWOT Analysis, By Factor (political & legal, economic and technological)
  • Fig. 19 Porter's Five Forces Analysis
  • Fig. 20 Strategy framework
  • Fig. 21 Participant categorization
  • Fig. 22 U.S. clinical oncology NGS market: Technology outlook key takeaways
  • Fig. 23 U.S. clinical oncology NGS market: Technology movement analysis
  • Fig. 24 Whole genome sequencing for U.S. clinical oncology market, 2018 - 2030 (USD Million)
  • Fig. 25 Whole exome sequencing for U.S. clinical oncology market, 2018 - 2030 (USD Million)
  • Fig. 26 Targeted sequencing and resequencing for U.S. clinical oncology market, 2018 - 2030 (USD Million)
  • Fig. 27 U.S. clinical oncology NGS market: Workflow outlook key takeaways
  • Fig. 28 U.S. clinical oncology NGS market: Workflow movement analysis
  • Fig. 29 NGS pre-sequencing for U.S. clinical oncology market, 2018 - 2030 (USD Million)
  • Fig. 30 NGS sequencing for U.S. clinical oncology market, 2018 - 2030 (USD Million)
  • Fig. 31 NGS data analysis for U.S. clinical oncology market, 2018 - 2030 (USD Million)
  • Fig. 32 U.S. clinical oncology NGS market: Application outlook key takeaways
  • Fig. 33 U.S. clinical oncology NGS market: Application movement analysis
  • Fig. 34 Screening clinical oncology NGS market, 2018 - 2030 (USD Million)
  • Fig. 35 Sporadic cancer screening U.S. clinical oncology NGS market, 2018 - 2030 (USD Million)
  • Fig. 36 Lifetime cancer risks for common cancers
  • Fig. 37 Inherited cancer screening U.S. clinical oncology NGS market, 2018 - 2030 (USD Million)
  • Fig. 38 Companion diagnostics U.S. clinical oncology NGS market, 2018 - 2030 (USD Million)
  • Fig. 39 Other diagnostics U.S. clinical oncology NGS market, 2018 - 2030 (USD Million)
  • Fig. 40 U.S. clinical oncology NGS market, 2018 - 2030 (USD Million)
  • Fig. 41 Key companies profiled